专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 外观设计

USD643856S1 Air cylinder 有权
标题翻译：气缸
公开(公告)号：USD643856S1
公开(公告)日：2011-08-23
申请号：US29354602
申请日：2010-01-26
申请人： Masaru Taniguchi , Jun Yamada
设计人： Masaru Taniguchi , Jun Yamada

12. 发明授权

US07928088B2 Th1 cell differentiation accelerator 失效
标题翻译： Th1细胞分化促进剂
公开(公告)号：US07928088B2
公开(公告)日：2011-04-19
申请号：US11939920
申请日：2007-11-14
申请人： Masaru Taniguchi , Toshinori Nakayama , Ikuya Yano , Takashi Naka
发明人： Masaru Taniguchi , Toshinori Nakayama , Ikuya Yano , Takashi Naka
IPC分类号： A61K31/70
CPC分类号： A61K31/739 , C07H3/06 , C12N5/0636 , C12N2501/90
摘要： The present invention provides an agent for promoting human Th1 cell differentiation and an agent for suppressing human Th2 cell differentiation, comprising lipoarabinomannans and/or lipomannans derived from BCG cell bodies. The agent of the present invention is useful as a prophylactic/therapeutic agent for cancers and the like, and also as a therapeutic agent for allergic diseases such as pollinosis.
摘要翻译：本发明提供了促进人Th1细胞分化的药剂和抑制人Th2细胞分化的药剂，其包含衍生自BCG细胞体的脂褐素甘露聚糖和/或脂甘露聚糖。本发明的药剂可用作癌症等的预防/治疗剂，也可用作花粉病等过敏性疾病的治疗剂。

13. 发明授权

US07805294B2 Wireless communication apparatus and wireless communication method 有权
标题翻译：无线通信装置和无线通信方法
公开(公告)号：US07805294B2
公开(公告)日：2010-09-28
申请号：US11663273
申请日：2005-09-16
申请人： Masaru Taniguchi
发明人： Masaru Taniguchi
IPC分类号： G10L19/14 , G10L11/06 , G10L19/00 , H03K7/06
CPC分类号： H04L27/12 , G10L25/78 , H03G3/342 , H04L27/0008
摘要： When a sound presence/absence detector (12) detects a sound absence interval, a non-modulated carrier signal is outputted in an area used to transmit speech data that are included in transmission data having a frame structure and that correspond to the sound absence interval. That is, an FSK modulator (14) causes a transmitting circuit (15) to output the non-modulated carrier signal from a wireless communication apparatus (100) in the area used to transmit the speech data corresponding to the sound absence interval. In the meantime, a four-level FSK modulated wave signal is outputted in the areas other than the one of the sound absence interval. A non-modulation discriminating data for allowing the sound absence interval to be determined are included in an area of channel identifying information included in the transmission data having the frame structure, and allow a communication terminal apparatus at the receiving end to avoid any unstable operations. The present invention is suitable for narrowed bands of communication paths and reduces the affections on adjacent channels.
摘要翻译：当声音存在/不存在检测器（12）检测到声音不存在间隔时，在用于发送语音数据的区域中输出未调制载波信号，所述区域包括在具有帧结构的传输数据中并且对应于声音不存在间隔。也就是说，FSK调制器（14）使得发射电路（15）在用于发送对应于声音无间隔的语音数据的区域中从无线通信设备（100）输出未调制的载波信号。同时，在声音不存在间隔之外的区域中输出四级FSK调制波信号。用于允许确定声音间隔的非调制识别数据被包括在包括在具有帧结构的传输数据中的信道识别信息的区域中，并允许接收端的通信终端设备避免任何不稳定的操作。本发明适用于通信路径的窄带，减少对相邻信道的影响。

14. 发明申请

US20100104632A1 Drug Having Regulatory Cell Ligand Contained in Liposome 有权
标题翻译：含有调节细胞配体的药物包含在脂质体中
公开(公告)号：US20100104632A1
公开(公告)日：2010-04-29
申请号：US12687728
申请日：2010-01-14
申请人： Yasuyuki Ishii , Risa Nozawa , Masaru Taniguchi
发明人： Yasuyuki Ishii , Risa Nozawa , Masaru Taniguchi
IPC分类号： A61K9/127 , A61K31/70 , A61P37/06 , A61P1/16
CPC分类号： A61K9/127 , A61K31/4745 , A61K31/7028 , A61K31/7032 , A61K31/7088 , A61K31/728
摘要： A liposome containing a regulatory cell ligand such as α-galactosyl ceramide or β-galactosyl ceramide is employed as the active ingredient of a drug for preventing or treating immune diseases etc.
摘要翻译：使用含有调节性细胞配体如α-半乳糖基神经酰胺或β-半乳糖神经酰胺的脂质体作为预防或治疗免疫疾病等的药物的活性成分。

15. 发明申请

US20090162869A1 MEMBRANE MOLECULE EXPRESSED SPECIFICALLY IN ACTIVATED PLASMACYTOID DENDRITIC CELL 审中-公开
标题翻译：活化的PLASMACYTOID DENDRITIC细胞中特异性表达的膜分子
公开(公告)号：US20090162869A1
公开(公告)日：2009-06-25
申请号：US12093501
申请日：2006-11-14
申请人： Hiroshi Watarai , Etsuko Sekine , Masaru Taniguchi
发明人： Hiroshi Watarai , Etsuko Sekine , Masaru Taniguchi
IPC分类号： G01N33/53 , C07K14/46 , C12N15/12 , C12N15/63 , C07K16/18 , C12N1/19 , C12N1/15 , C12N5/10
CPC分类号： C07K14/47 , C07K16/28 , C07K2317/75
摘要： It is an object of the present invention to identify a membrane molecule that is specifically expressed on activated plasmacytoid dendritic cells, for the purpose of preventing or improving affection or disease such as cancer, autoimmune disease, allergy, or infectious disease by regulating the functions of dendritic cells capable of integrating an immune system. The present invention provides a protein having any one of the following amino acid sequences:(a) an amino acid sequence as shown in SEQ ID NO: 2; (b) an amino acid sequence, which comprises a deletion, substitution, insertion and/or addition of one or several amino acid residues with respect to the amino acid sequence as shown in SEQ ID NO: 2, and which is capable of regulating the functions of dendritic cells; and (c) an amino acid sequence, which has homology of 80% or more with the amino acid sequence as shown in SEQ ID NO: 2, and which is capable of regulating the functions of dendritic cells.
摘要翻译：本发明的目的是鉴定在激活的浆细胞样树突状细胞上特异性表达的膜分子，以通过调节功能来预防或改善感染或疾病如癌症，自身免疫性疾病，变态反应或感染性疾病能够整合免疫系统的树突状细胞。本发明提供具有以下氨基酸序列之一的蛋白质：（a）SEQ ID NO：2所示的氨基酸序列; （b）氨基酸序列，其包含相对于SEQ ID NO：2所示的氨基酸序列的一个或几个氨基酸残基的缺失，取代，插入和/或添加，并且其能够调节树突细胞的功能; 和（c）氨基酸序列，与SEQ ID NO：2所示的氨基酸序列具有80％以上的同源性，能够调节树突细胞的功能。

16. 发明授权

US08945922B2 Generating a mature NKT cell from a reprogrammed somatic cell with a T-cell antigen receptor α-chain region rearranged to uniform Va-Ja in a NKT-cell specific way 有权
标题翻译：从具有T细胞抗原受体α链区域的重编程体细胞产生成熟的NKT细胞，以NKT细胞特异性方式重排为均匀的Va-Ja
公开(公告)号：US08945922B2
公开(公告)日：2015-02-03
申请号：US13062453
申请日：2009-09-08
申请人： Hiroshi Watarai , Haruhiko Koseki , Masaru Taniguchi , Shin-ichiro Fujii
发明人： Hiroshi Watarai , Haruhiko Koseki , Masaru Taniguchi , Shin-ichiro Fujii
IPC分类号： C12N5/02 , A61K31/7036 , C12N5/0783 , C12N5/074 , A61K35/12
CPC分类号： A61K31/7036 , A61K35/12 , C12N5/0646 , C12N5/0696 , C12N2501/23 , C12N2501/2302 , C12N2501/2307 , C12N2501/2315 , C12N2501/26 , C12N2501/42 , C12N2501/60 , C12N2501/602 , C12N2501/603 , C12N2501/604 , C12N2501/606 , C12N2506/11 , C12N2506/45
摘要： Provided are an iPS cell derived from a somatic cell such as an NKT cell, having the α-chain region of the T cell antigen receptor gene rearranged to uniform Vα-Jα in an NKT cell receptor-specific way, NKT cells differentiated from the iPS cell, a method of creating the same, and an immune cell therapy agent prepared using cells differentiated from the iPS cell. Also provided are an iPS cell having TCRα rearranged to NKT-TCR (NKT-iPS cell), obtained by contacting a somatic cell, such as an NKT cell, having the α-chain region of the T cell antigen receptor gene rearranged to uniform Vα-Jα in an NKT cell receptor-specific way, with nuclear reprogramming factors, isolated NKT cells obtained by differentiating the iPS cell ex vivo (iPS-NKT cell), a method of generating CD4/CD8-double positive NKT cells (DP-NKT cells) and mature NKT cells from NKT-iPS cells by altering the combination of feeder cells and/or cytokines, a method of expanding the iPS-NKT cells, and an NKT cell cytotherapy agent comprising NKT cells activated with α-galactosyl ceramide (α-GalCer), or iPS-NKT cells, and α-GalCer in combination.
摘要翻译：提供衍生自体细胞如NKT细胞的iPS细胞，其具有T细胞抗原受体基因的α链区域以NKT细胞受体特异性方式重排为均匀的Vα-Jα，从iPS分化的NKT细胞细胞，其制备方法以及使用从iPS细胞分化的细胞制备的免疫细胞治疗剂。还提供了将具有重排为T细胞抗原受体基因的α-链区域的体细胞例如NKT细胞与NKT-TCR（NKT-iPS细胞）重排的TCRα的iPS细胞重排为均匀的Vα -Jα以NKT细胞受体特异性方式，具有核重编程因子，通过离体iPS细胞（iPS-NKT细胞）分化获得的分离的NKT细胞，产生CD4 / CD8-双重阳性NKT细胞的方法（DP-NKT 细胞）和来自NKT-iPS细胞的成熟NKT细胞，通过改变饲养细胞和/或细胞因子的组合，扩增iPS-NKT细胞的方法和包含用α-半乳糖基神经酰胺（α）活化的NKT细胞的NKT细胞细胞治疗剂 -GalCer）或iPS-NKT细胞和α-GalCer组合。

17. 发明授权

US08853173B2 Synthetic glycolipid and use thereof 有权
标题翻译：合成糖脂及其用途
公开(公告)号：US08853173B2
公开(公告)日：2014-10-07
申请号：US13577159
申请日：2011-02-04
申请人： Takuya Tashiro , Kenji Mori , Masao Shiozaki , Masaru Taniguchi , Hiroshi Watarai
发明人： Takuya Tashiro , Kenji Mori , Masao Shiozaki , Masaru Taniguchi , Hiroshi Watarai
IPC分类号： C07H17/02 , A61K31/7028 , A61P31/04 , A61K31/7032 , C07H15/04
CPC分类号： C07H15/04 , A61K31/7032
摘要： A compound represented by the following formula (1): wherein R1 is an aldopyranose residue wherein the 6-hydroxyl group is optionally alkylated, R2 is a C1-26 hydrocarbon group optionally having substituent(s), R3 is a hydrogen atom or a C1-26 hydrocarbon group optionally having substituent(s), R4 is a C1-21 hydrocarbon group optionally having substituent(s), X is an oxygen atom or —CH2—, and Y is —CH2—, —CH(OH)— or —CH═CH—, or a salt thereof is useful for the prophylaxis or treatment of cancer or infection, since it can preferentially induce production of IFN-γ of NKT cells.
摘要翻译：由下式（1）表示的化合物：其中R1是吡喃葡萄糖残基，其中6-羟基任选被烷基化，R 2是任选具有取代基的C 1-26烃基，R 3是氢原子或C 1 -26任选具有取代基的烃基，R4是任选具有取代基的C 1-12烃基，X是氧原子或-CH 2 - ，Y是-CH 2 - ， - CH（OH） - 或 -CH = CH-或其盐可用于预防或治疗癌症或感染，因为其可优先诱导NKT细胞的IFN-γ的产生。

18. 发明授权

US08454955B2 Methods for treating allergic airway inflammation, airway hypersensitivity, and eosinophilia 有权
标题翻译：用于治疗过敏性气道炎症，气道超敏反应和嗜酸性粒细胞增多的方法
公开(公告)号：US08454955B2
公开(公告)日：2013-06-04
申请号：US12745139
申请日：2008-08-29
申请人： Hiroshi Watarai , Masaru Taniguchi
发明人： Hiroshi Watarai , Masaru Taniguchi
IPC分类号： A61K39/395
CPC分类号： C07K16/2866 , G01N33/505 , G01N33/6869
摘要： The invention provides a method of screening a therapeutic agent for allergic airway inflammation and/or airway hypersensitivity, comprising using an IL-17RB positive NKT cell, as well as a therapeutic agent for allergic airway inflammation and/or airway hypersensitivity, containing a substance capable of inhibiting or eliminating the Th2 cell-like function of an IL-17RB positive NKT cell as an active ingredient.
摘要翻译：本发明提供筛选过敏性气道炎症和/或气道超敏反应的治疗剂的方法，其包括使用IL-17RB阳性NKT细胞，以及用于过敏性气道炎症和/或气道超敏反应的治疗剂，其含有能够抑制或消除作为活性成分的IL-17RB阳性NKT细胞的Th2细胞样功能。

19. 发明授权

US08299223B2 Pseudoglycolipid and use thereof 有权
标题翻译：假糖脂及其用途
公开(公告)号：US08299223B2
公开(公告)日：2012-10-30
申请号：US12528232
申请日：2008-02-22
申请人： Takuya Tashiro , Kenji Mori , Ken-ichi Fuhshuku , Masaru Taniguchi , Ryusuke Nakagawa , Hiroshi Watarai
发明人： Takuya Tashiro , Kenji Mori , Ken-ichi Fuhshuku , Masaru Taniguchi , Ryusuke Nakagawa , Hiroshi Watarai
IPC分类号： C07H17/02
CPC分类号： C07C235/08 , C07C233/18 , C07C233/36 , C07C323/41 , C07C2601/14
摘要： The invention provides a pseudoglycolipid effective for cancer treatment and the like and a novel synthesis intermediate therefor, as well as a medicament containing the pseudoglycolipid and the like. The inventive compound is represented by the formula (1), or a salt thereof, wherein each symbol is as defined in the specification.
摘要翻译：本发明提供了对癌症治疗等有效的假性糖脂及其中间体的新型合成物，以及含有假糖脂等的药物。本发明化合物由式（1）表示，或其盐，其中每个符号如说明书中所定义。

20. 发明授权

US08173608B2 Compound having cyclic structure and use thereof 有权
标题翻译：具有环状结构的化合物及其用途
公开(公告)号：US08173608B2
公开(公告)日：2012-05-08
申请号：US11817616
申请日：2006-03-03
申请人： Ken-ichi Fuhshuku , Kenji Mori , Takuya Tashiro , Masaru Taniguchi , Ken-ichiro Seino
发明人： Ken-ichi Fuhshuku , Kenji Mori , Takuya Tashiro , Masaru Taniguchi , Ken-ichiro Seino
IPC分类号： A01N43/04 , A61K31/70 , C07G3/00 , C07H17/02
CPC分类号： C07D207/12 , C07D205/04 , C07D405/12 , C07F7/1804 , C07H15/26
摘要： The present invention relates to a compound represented by the following formula (1′) wherein R is an aldopyranose residue, R2 is a C2-18 hydrocarbon group optionally having substituent(s), R3 is an acyl group, X is an oxygen atom, a sulfur atom or —NH—, and p is an integer of 0-4, or a salt thereof. The compound of the present invention has a specific immunoregulatory ability, and is useful for the prophylaxis or treatment of autoimmune diseases and the like.
摘要翻译：本发明涉及由下式（1'）表示的化合物，其中R为吡喃葡萄糖残基，R2为任选具有取代基的C2-18烃基，R3为酰基，X为氧原子，硫原子或-NH-，p为0-4的整数，或其盐。本发明的化合物具有特异的免疫调节能力，可用于预防或治疗自身免疫性疾病等。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式